Cytek Biosciences Past Earnings Performance
Past criteria checks 0/6
Cytek Biosciences's earnings have been declining at an average annual rate of -41.2%, while the Life Sciences industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 19.1% per year.
Key information
-41.2%
Earnings growth rate
19.1%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 19.1% |
| Return on equity | -4.5% |
| Net Margin | -8.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
Sep 13
An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Aug 09Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Jul 27Checking In On Cytek Biosciences
Mar 23Revenue & Expenses Breakdown
How Cytek Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 198 | -18 | 91 | 42 |
| 31 Mar 24 | 201 | -12 | 92 | 44 |
| 31 Dec 23 | 193 | -12 | 92 | 44 |
| 30 Sep 23 | 183 | -14 | 90 | 43 |
| 30 Jun 23 | 176 | -6 | 85 | 41 |
| 31 Mar 23 | 166 | -2 | 77 | 37 |
| 31 Dec 22 | 164 | 2 | 68 | 35 |
| 30 Sep 22 | 155 | -1 | 63 | 32 |
| 30 Jun 22 | 148 | -3 | 59 | 30 |
| 31 Mar 22 | 139 | -2 | 52 | 27 |
| 31 Dec 21 | 128 | 0 | 46 | 24 |
| 30 Sep 21 | 120 | 1 | 37 | 22 |
| 30 Jun 21 | 110 | 2 | 31 | 19 |
| 31 Mar 21 | 99 | 4 | 27 | 16 |
| 31 Dec 20 | 93 | 3 | 24 | 14 |
| 31 Dec 19 | 58 | -17 | 17 | 9 |
Quality Earnings: CTKB is currently unprofitable.
Growing Profit Margin: CTKB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CTKB is unprofitable, and losses have increased over the past 5 years at a rate of 41.2% per year.
Accelerating Growth: Unable to compare CTKB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTKB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-11.3%).
Return on Equity
High ROE: CTKB has a negative Return on Equity (-4.51%), as it is currently unprofitable.